Browsing by Contributors Spigel, David R

فهرست الفبایی 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
آ ب پ ت ث ج چ ح خ د ذ ر ز ژ س ش ص ض ط ظ ع غ ف ق ک گ ل م ن و ه ی
 
Showing results 1 to 9 of 9
PreviewIssue DateTitleContributor(s)
2017 JConcology Volume 35 Issue 25 September (16).pdf.jpg2017Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non – Small Cell Lung CancersKris, Mark G; Gaspar, Laurie E; Chaft, Jamie E; Kennedy, Erin B; Azzoli, Christopher G; Ellis, Peter M; Lin, Steven H; Pass, Harvey I; Seth, Rahul; Shepherd, Frances A; Spigel, David R; Strawn, John R; Ung, Yee C; Weyant, Michael
2014medicine article k (619).pdf.jpg2014Carcinoma of Unknown Primary SiteSpigel, David R; Hainsworth, John D; Greco, F Anthony
2018 CANSER Volume 124 Issue 11 June (23).pdf.jpg2018Erlotinib Plus Either Pazopanib or Placebo in Patients With Previously Treated Advanced Non – Small Cell Lung Cancer : A Randomized , Placebo-Controlled Phase 2 Trial With Correlated Serum Proteomic SignaturesSpigel, David R; Iii, Howard A Burris; Greco, F Anthony; Shih, Kent C; Gian, Victor G
2015 NEJM Volume 373 Issue 17 October (16).pdf.jpg2015Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.Borghaei, Hossein; Paz-Ares, Luis; Horn, Leora; Spigel, David R; Steins, Martin; Ready, Neal E; Chow, Laura Q; Vokes, Everett E; Felip, Enriqueta; Holgado, Esther; Barlesi, Fabrice; Kohlhäufl, Martin; Arrieta, Oscar; Burgio, Marco Angelo; Fayette, Jérôme; Lena, Hervé; Po
2015 NEJM Volume 373 Issue 2 July (9).pdf.jpg2015Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.Borghaei, Hossein; Paz-Ares, Luis; Horn, Leora; Spigel, David R; Steins, Martin; Ready, Neal E; Chow, Laura Q; Vokes, Everett E; Felip, Enriqueta; Holgado, Esther; Barlesi, Fabrice; Kohlhäufl, Martin; Arrieta, Oscar; Burgio, Marco Angelo; Fayette, Jérôme; Lena, Hervé; Po
2017 JCO Volume 35 Issue 35 December (6).pdf.jpg2017Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non – Small-Cell Lung Cancer : Two-Year Outcomes From Two Randomized , Open-Label , Phase III Trials ( CheckMate 017 and CheckMate 057 )Horn, Leora; Spigel, David R; Vokes, Everett E; Holgado, Esther; Ready, Neal; Steins, Martin; Poddubskaya, Elena; Borghaei, Hossein; Felip, Enriqueta; Paz-ares, Luis; Pluzanski, Adam; Reckamp, Karen L; Burgio, Marco A; Crin, Lucio; Reck, Martin; Hellmann, Matthew D; Gees
2018 CANSER Volume 124 Issue 9 May (20).pdf.jpg2018Randomized Phase 2 Trial of Pemetrexed , Pemetrexed / Bevacizumab , and Pemetrexed / Carboplatin / Bevacizumab in Patients With Stage IIIB / IV Non – Small Cell Lung Cancer and an Eastern Cooperative Oncology Group Performance Status of 2Spigel, David R; Hainsworth, John D; Joseph, Mathew J; Shipley, Dianna L
2018 JCO Volume 36 Issue 23 August (15).pdf.jpg2018Reply to J . J . Tao et al No relationship to disclose combinationHurwitz, Herbert; Spigel, David R; Sweeney, Christopher; Burris, Howard; Sweeney, Christopher
2017 JCO Volume 35 Issue 4 February (6).pdf.jpg2017Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non – Small Cell Lung Cancer : METLungSpigel, David R; Edelman, Martin J; Byrne, Kenneth O; Paz-ares, Luis; Mocci, Simonetta; Phan, See; Shames, David S; Smith, Dustin; Yu, Wei; Paton, Virginia E; Mok, Tony